Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company developing humanized monoclonal antibody therapies for biomarker-defined cancer populations, with lead candidate sirexatamab (anti-DKK1) in Phase 2 trials across five cancer indications. The Cambridge, MA-based company is publicly traded on Nasdaq (LPTX) and operates as a subsidiary of Cypherpunk Technologies Inc.
- Company typePublic
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Leap Therapeutics does
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing humanized monoclonal antibody therapeutics for biomarker-defined cancer populations. The company is headquartered in Cambridge, Massachusetts, trades on Nasdaq under ticker LPTX, and operates as a subsidiary of Cypherpunk Technologies Inc., a cryptocurrency-focused holding company. Leap's pipeline is centered on three antibody programs: sirexatamab (DKN-01), a humanized anti-DKK1 monoclonal antibody and the most advanced clinical candidate, currently in Phase 2 development across five cancer indications (gastric, colorectal, endometrial, prostate, and non-small cell lung cancer); FL-301, an anti-Claudin18.2 antibody for gastric and pancreatic cancer; and FL-501, an anti-GDF-15 antibody in preclinical development for cancer cachexia and tumor immunosuppression.
The company's underlying technology combines targeted antibody engineering with a proprietary biomarker-driven patient selection approach. DKK1 expression in tumors is identified using RNAscope chromogenic in situ hybridization, with an H-Score applied by pathologists to stratify patients most likely to respond to sirexatamab therapy. Mechanistically, sirexatamab removes free DKK1 from the tumor microenvironment, suppressing MDSC-mediated immunosuppression, reducing angiogenesis, activating NK cells, and—when combined with anti-PD-1 agents—inducing a pro-inflammatory tumor microenvironment. Active clinical trials include the DisTinGuish study (combination with BeiGene's tislelizumab in gastric cancer), the WaKING study (combination with Roche's atezolizumab, sponsored by The Royal Marsden Hospital in the UK), the DeFianCe study (combination with bevacizumab in colorectal cancer), and a Phase 2 endometrial cancer study in combination with pembrolizumab.
Leap's business model is pre-commercial: the company has no approved products and no current revenue. Its go-to-market strategy is to advance candidates through clinical development to regulatory approval and then commercialize through standard pharmaceutical distribution channels, including potential partnerships with larger pharmaceutical companies for co-development and commercialization. The company maintains a small headcount (11–50 employees) and finances operations through equity capital markets, most recently via a $58.88 million private placement led by Winklevoss Capital to its parent company. The customer base consists of clinical trial patients across multiple oncology indications rather than paying commercial customers.
Leap Therapeutics firmographics
Firmographics- Name
- Leap Therapeutics
- Legal name
- Leap Therapeutics, Inc.
- Website
- https://leaptx.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Leap Therapeutics is a clinical-stage biopharmaceutical company developing humanized monoclonal antibody therapies for biomarker-defined cancer populations, with lead candidate sirexatamab (anti-DKK1) in Phase 2 trials across five cancer indications. The Cambridge, MA-based company is publicly traded on Nasdaq (LPTX) and operates as a subsidiary of Cypherpunk Technologies Inc.
- Ownership category
- akta.pro rank
Leap Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Leap Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Leap Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Drug Development and Commercialization: Leap Therapeutics is a clinical-stage biopharmaceutical company with no current revenue. The company is focused on developing targeted and immuno-oncology therapeutics, with the goal of obtaining regulatory approval and commercializing its drug candidates. Revenue will be generated through product sales following regulatory approval. The company is listed on Nasdaq (LPTX) and is a subsidiary of Cypherpunk Technologies Inc.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Leap Therapeutics product offering
Product offeringCore offering
Leap Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based targeted cancer therapies. Its pipeline focuses on monoclonal antibodies designed to modulate key signaling pathways in oncology, including investigational candidates sirexatamab (DKN-01), FL-301, and FL-501 for solid tumors.
Product overview
Leap Therapeutics is a biomarker-focused oncology drug development company developing a pipeline of targeted and immuno-oncology therapeutics. The company's portfolio consists of three core product candidates: Sirexatamab (DKN-01), an anti-DKK1 antibody currently in Phase 2 clinical trials for multiple cancer indications including gastric, colorectal, endometrial, prostate, and lung cancers; FL-501, an anti-GDF-15 antibody in preclinical development targeting cancer cachexia and immunosuppression; and FL-301, an anti-Claudin18.2 antibody in development for gastric and pancreatic cancers. The company focuses on identifying specific biomarkers to predict which patients are more likely to respond to and have better survival outcomes on their therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Sirexatamab (DKN-01) Sirexatamab (DKN-01) is a monoclonal antibody targeting the DKK1 pathway, under clinical development as a targeted cancer therapy for solid tumors.
- FL-301 FL-301 is an investigational antibody-based oncology therapeutic candidate in clinical development by Leap Therapeutics.
- FL-501 FL-501 is an investigational antibody-based oncology therapeutic candidate in clinical development by Leap Therapeutics.
Quantifiable outcome
- DKK1-high cancer patients have approximately 2.5 years shorter overall survival compared to DKK1-low patients
- +4 more outcomes
Companies that use Leap Therapeutics
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Leap Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Leap Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- ZODL (Zcash Open Development Lab)minorCypherpunk Technologies made a $5 million strategic investment in ZODL, the development team behind the Zodl Zcash wallet. This investment is made through Cypherpunk Technologies and represents a strategic investment rather than a core pharmaceutical partnership.
- BeiGenecoreLeap's DisTinGuish study (NCT04363801) evaluates sirexatamab (DKN-01) in combination with tislelizumab (BeiGene's anti-PD-1 antibody) and standard-of-care chemotherapy in patients with inoperable, locally advanced HER2-negative gastric/gastroesophageal junction adenocarcinoma. This is a co-development collaboration for the Phase 2 study.
- Roche / imCORE NetworkcoreThe WaKING study (NCT04166721) is an investigator-sponsored trial of sirexatamab (DKN-01) in combination with atezolizumab (Roche's anti-PD-L1 antibody) in patients with microsatellite stable esophagogastric cancer. The study is sponsored by The Royal Marsden Hospital in the United Kingdom and is being funded by Roche as part of its imCORE network of cancer immunotherapy centers.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Leap Therapeutics competitors and assessment
Company assessmentDirect peers
- MacroGenics: Clinical-stage biopharmaceutical company developing multiple monoclonal antibody therapeutics for oncology, including checkpoint combinations. Shares Leap's mAb modality, clinical-stage profile, and combination-IO strategy.
- Bolt Biotherapeutics: Clinical-stage developer of antibody-based immuno-oncology therapeutics, including combinations with checkpoint inhibitors. Comparable to Leap in modality (engineered antibodies), stage, and combination development approach.
- Compugen: Clinical-stage company developing antibody-based immuno-oncology therapeutics using computational target discovery. Shares Leap's therapeutic antibody focus, biomarker-led strategy, and oncology combination positioning.
- Zymeworks: Clinical-stage developer of antibody-based therapeutics (including bispecifics) for oncology, with active combination programs in solid tumors. Overlaps with Leap in antibody modality, oncology focus, and clinical-stage pipeline.
- Elevation Oncology: Clinical-stage oncology company pursuing a biomarker-driven, patient-selection approach to antibody therapeutics. Like Leap, Elevation targets genomically/biomarker-defined subsets and combines novel antibodies with checkpoint inhibitors, making its development model and target market closely aligned.
- Harpoon Therapeutics: Clinical-stage developer of antibody-based oncology therapeutics (T cell engagers) acquired by Merck. Highly comparable in clinical-stage antibody-oncology positioning and combination IO strategies.
- Mersana Therapeutics: Clinical-stage developer of antibody-based oncology therapeutics with biomarker-focused patient selection. While focused on ADCs, Mersana shares Leap's clinical-stage antibody oncology profile and indication strategy.
- CytomX Therapeutics: Clinical-stage oncology company engineering antibody therapeutics (Probody platform) for tumor-selective activation. Comparable clinical-stage profile and antibody-oncology combination approach.
- Adagene: Clinical-stage antibody discovery and development company focused on oncology with computational platform-driven candidate selection. Overlaps with Leap in antibody modality, oncology focus, and biomarker-driven development philosophy.
Emerging players
- Akeso, Inc. Clinical-stage biopharmaceutical company developing novel antibody therapeutics including PD-1/CTLA-4 bispecifics in oncology. Comparable to Leap in antibody modality, oncology focus, and immuno-oncology combination development, though geographically rooted in China.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Leap Therapeutics social profiles
Digital presenceLeap Therapeutics compliance and trust
Trust signalCompliance4 records
Leap Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Leap Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Leap Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Leap Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Leap Therapeutics
What does Leap Therapeutics do?
Leap Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based targeted cancer therapies. Its pipeline focuses on monoclonal antibodies designed to modulate key signaling pathways in oncology, including investigational candidates sirexatamab (DKN-01), FL-301, and FL-501 for solid tumors.
Is Leap Therapeutics a public or private company?
Leap Therapeutics is a public company. It is classified as public and is currently operating.
When was Leap Therapeutics founded?
Leap Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Leap Therapeutics based?
Leap Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Leap Therapeutics make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Who are Leap Therapeutics's main competitors?
Direct peers on record are MacroGenics, Bolt Biotherapeutics, Compugen, Zymeworks, Elevation Oncology, Harpoon Therapeutics, Mersana Therapeutics, CytomX Therapeutics and Adagene. Akeso, Inc. is listed as an emerging player.
Does Leap Therapeutics have an API?
No public API is recorded for Leap Therapeutics.
What industry is Leap Therapeutics in?
Leap Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2836.